Chakrapani Ayurveda Clinic & Research Center

5 records, newest first. Each line links to the FDA page it came from.

Refusal charges, in plain English

• UNAPPROVED2 refused lines

  Unapproved new drug

  The product appeared to be a new drug within the meaning of section 201(p) of the FD&C Act without an approved New Drug Application. FDA can apply this charge to a food or supplement whose labeling presents it for drug uses.

Questions about Chakrapani Ayurveda Clinic & Research Center

Is Chakrapani Ayurveda Clinic & Research Center on an FDA import alert?

Yes. As of October 26, 2026, Chakrapani Ayurveda Clinic & Research Center is on the red list of FDA Import Alert 54-14, “Supplements from firms not meeting supplement GMP”, for sanshamani; gokshuradi guggul; yograj guggul powder; triphala guggul powder; kaishore guggul powder; shwas (asthma help) herbal tea; medohar (obesity help) herbal tea; avipattikar; mahasudarshan; kanchanar guggul powder; mansyadi; FDA published the listing on June 8, 2023.

Has FDA refused shipments from Chakrapani Ayurveda Clinic & Research Center?

Yes. FDA refused 2 shipment lines from Chakrapani Ayurveda Clinic & Research Center on July 31, 2023. The most recent, on July 31, 2023, was vitamin, mineral, proteins and unconventional dietary specialities for humans and animals, n.e.c., charged as UNAPPROVED (unapproved new drug).

Why did FDA refuse Chakrapani Ayurveda Clinic & Research Center's shipments?

The most frequent charge is UNAPPROVED (unapproved new drug, 2 lines).

When was Chakrapani Ayurveda Clinic & Research Center last inspected by FDA?

FDA's most recent inspection of Chakrapani Ayurveda Clinic & Research Center with a final classification is dated February 18, 2022 and was classified OAI (Official Action Indicated).

What is Chakrapani Ayurveda Clinic & Research Center's FEI number?

Chakrapani Ayurveda Clinic & Research Center's FDA Establishment Identifier (FEI) is 3010119975.

Can shipments from Chakrapani Ayurveda Clinic & Research Center still enter the U.S.?

Shipments of sanshamani; gokshuradi guggul; yograj guggul powder; triphala guggul powder; kaishore guggul powder; shwas (asthma help) herbal tea; medohar (obesity help) herbal tea; avipattikar; mahasudarshan; kanchanar guggul powder; mansyadi from Chakrapani Ayurveda Clinic & Research Center can be detained without physical examination under Import Alert 54-14; FDA releases them only if evidence shows they do not have the listed violation. Importers must consider this listing in their FSVP evaluation (21 CFR 1.505).